Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 101 references
Medicine
TL;DR
The structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment are reviewed.
Abstract
The poliovirus receptor (CD155) is an emerging immune checkpoint molecule involved in the suppression of anti-tumor immunity. In ovarian cancer, CD155 is frequently overexpressed and interacts with receptors such as TIGIT, CD96, and CD226 to modulate the activity of T cells, NK cells, and dendritic cells. These interactions contribute to immune cell exhaustion, regulatory T cell expansion, and impaired cytotoxic responses, facilitating tumor immune evasion. Recent studies have revealed that CD155 expression is influenced by tumor metabolism, autophagy, and cytokine signaling. Therapeutic strategies targeting the CD155 axis—through monoclonal antibodies, bispecific constructs, or engineered T/NK cells—are being actively explored and show promise in enhancing anti-tumor responses, particularly when combined with existing checkpoint inhibitors. This review provides a comprehensive overview of the structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment. We discuss the signaling mechanisms of the TIGIT/CD96/CD226 axis, its impact on diverse immune cell populations, and the current landscape of therapeutic strategies targeting this pathway. Finally, we evaluate the potential of CD155 and its receptors as predictive biomarkers and therapeutic targets to overcome immune resistance and improve outcomes in ovarian cancer.
This review systematically integrates and finds that TGF-β not only directly suppresses NK cell function but also upregulates cluster of differentiation 155 (CD155) expression on tumor cells through both classical and non-classical pathways, able to amplify TIGIT-mediated negative signaling.
Shu-Yun Liu· International Journal of Bio...· 0 citations
This study identified TIGIT KO as a potent enhancer of AdCAR-T-cell function and supports ICR gene disruption as a promising approach to improve therapeutic efficacy while reducing the systemic toxicities commonly associated with ICI therapy.
Anna-Sophia Mast, D. Atar, Lara Ruoff et al.· Oncoimmunology· 0 citations
Current findings position B7-H6 as a promising immuno-oncologic target at the intersection of immune surveillance, immune escape, and malignant progression, warranting continued investigation as a next-generation therapeutic axis in cancer immunotherapy.
Ziyi Yang, Qi Zhao· Cancer Biome and Targeted Th...· 0 citations
CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immunity involving T cells and natural killer (NK) cells. Aberrant CD58 expression, resulting from genomic inactivation, epigenetic silencing, transcript...
Peng-Fei Guo, Ming Yi, Yu-Jie Gan et al.· Molecular Cancer· 0 citations
In vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 and CD38 exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells.
Chaofan Wang, Wanting Wang, Mo-Ran Wang et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.